SHH and neoplasm: These findings complement previous reports that active SHH signaling limits tumor progression in the bladder (Kim et al., 2019; Shin et al., 2011), and suggest that restoration of SHH signaling may be a therapeutic option in urothelial carcinomas with inactivated PPARG.